BIO-TECHNE Corp (TECH) stock
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3040% above fair value
$72.80−0.02 (-0.03%)
Close on Nov 11, 2026Market cap $11.43BP/E 66.8Yield 0.44%
Bio-Techne ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Bio-Techne's ebitda for the twelve months ending Sep 30, 2026 was $337.58M, up 56.3% year over year. For fiscal 2026 it was $349.25M, up 64.6% from the year before. Over ten years it grew 6.1% a year on average. The highest annual figure on record is $406.18M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $349.25M | +64.6% |
| FY2025 | Jun 30, 2025 | $212.16M | -33.4% |
| FY2024 | Jun 30, 2024 | $318.40M | -21.6% |
| FY2023 | Jun 30, 2023 | $406.18M | +2.1% |
| FY2022 | Jun 30, 2022 | $397.66M | +22.3% |
| FY2021 | Jun 30, 2021 | $325.04M | +35.3% |
| FY2020 | Jun 30, 2020 | $240.16M | +6.8% |
| FY2019 | Jun 30, 2019 | $224.89M | +12.1% |
| FY2018 | Jun 30, 2018 | $200.64M | +11.1% |
| FY2017 | Jun 30, 2017 | $180.62M | -6.6% |
| FY2016 | Jun 30, 2016 | $193.36M | +4.9% |
| FY2015 | Jun 30, 2015 | $184.25M | +3.0% |
| FY2014 | Jun 30, 2014 | $178.93M | +1333.8% |
| FY2013 | Jun 30, 2013 | $12.48M | -93.0% |
| FY2012 | Jun 30, 2012 | $178.68M | +4.0% |
| FY2011 | Jun 30, 2011 | $171.76M | +4.4% |
| FY2010 | Jun 30, 2010 | $164.46M | +3.7% |
| FY2009 | Jun 30, 2009 | $158.55M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $60.33M | -16.2% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $98.42M | +2927.3% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $99.66M | +50.4% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $79.17M | +6.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $72.00M | +5.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $3.25M | -95.6% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $66.28M | -29.7% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $74.50M | +13.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $68.12M | -19.3% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $73.88M | -39.2% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $94.31M | -12.0% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $65.81M | -30.4% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $84.40M | +1.7% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $121.45M | +14.1% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $107.18M | -7.5% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $94.59M | +8.2% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $82.96M | -5.7% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $106.44M | +14.1% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $115.81M | +29.1% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $87.45M | +21.7% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $87.96M | +25.3% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $93.25M | +54.6% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $89.73M | +30.2% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $71.88M | +24.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $70.18M | +31.4% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $60.30M | -4.6% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $68.90M | +8.7% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $57.55M | +7.6% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $53.41M | +19.2% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $63.18M | +5.2% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $63.41M | +6.8% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $53.48M | +34.5% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $44.82M | +8.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $60.07M | +9.6% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $59.36M | +19.8% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $39.76M | +18.7% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $41.45M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $54.79M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $49.54M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $33.49M | – |
See a number that looks wrong?